Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 90240B106 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Biotechnology Value Fund L P
13G
|
6.1% |
9/21/2026
Event 9/14/2026
|
|
| Biotechnology Value Fund L P | 3.2% | ||
| BVF I GP LLC | 3.2% | ||
| Biotechnology Value Fund II LP | 2.4% | ||
| BVF II GP LLC | 2.4% | ||
| Biotechnology Value Trading Fund OS LP | 0.4% | ||
| BVF Partners OS Ltd. | 0.4% | ||
| BVF GP Holdings LLC | 5.6% | ||
| BVF Partners L P/IL | 6.1% | ||
| BVF Inc/IL | 6.1% | ||
| Lampert Mark N | 6.1% | ||
|
RA Capital Management, L.P.
13D/A
Amendment 7
|
19.9% |
9/17/2026
Event 9/15/2026
|
|
| RA Capital Management, L.P. | 19.9% | ||
| Peter Kolchinsky | 19.9% | ||
| Rajeev Shah | 19.9% | ||
| RA Capital Healthcare Fund, L.P. | 17.2% | ||
|
Paradigm Biocapital Advisors LP
13G
|
5.8% |
9/17/2026
Event 9/10/2026
|
|
| Paradigm BioCapital Advisors LP | 5.8% | ||
| Paradigm BioCapital Advisors GP LLC | 5.8% | ||
| Senai Asefaw, M.D. | 5.8% | ||
| Paradigm BioCapital International Fund Ltd. | 5.1% | ||
|
Nextech VI Oncology SCSp
13G/A
Amendment 2
|
6.0% |
8/14/2026
Event 6/30/2026
|
|
| Nextech VI Oncology SCSp | 6.0% | ||
| Nextech VI GP S.a. r.l. | 6.0% | ||
| Ian Charoub | 6.0% | ||
| Costas Constantinides | 6.0% | ||
| Rocco Sgobbo | 6.0% | ||
|
Farallon Capital Management, L.L.C.
13G/A
Amendment 2
|
0% |
8/14/2026
Event 6/30/2026
|
|
| Farallon Capital Management, L.L.C. | 0% | ||
| Farallon Capital Partners, L.P. | 0% | ||
| Farallon Capital Institutional Partners, L.P. | 0% | ||
| Farallon Capital Institutional Partners II, L.P. | 0% | ||
| Farallon Capital Institutional Partners III, L.P. | 0% | ||
| Four Crossings Institutional Partners V, L.P. | 0% | ||
| Farallon Capital Offshore Investors II, L.P. | 0% | ||
| Farallon Capital (AM) Investors, L.P. | 0% | ||
| Farallon Capital F5 Master I, L.P. | 0% | ||
| Farallon Healthcare Partners Master, L.P. | 0% | ||
| Farallon Partners, L.L.C. | 0% | ||
| Farallon Institutional (GP) V, L.L.C. | 0% | ||
| Farallon F5 (GP), L.L.C. | 0% | ||
| Farallon Healthcare Partners (GP), L.L.C. | 0% | ||
| Dapice Joshua J. | 0% | ||
| Dreyfuss, Philip D. | 0% | ||
| Dunn Hannah E. | 0% | ||
| Gehani, Varun N. | 0% | ||
| Giauque, Nicolas | 0% | ||
| Husen, Avner A. | 0% | ||
| Kim, David T. | 0% | ||
| Linn, Michael G. | 0% | ||
| Luo Patrick (Cheng) | 0% | ||
| Roberts, Jr., Thomas G. | 0% | ||
| Saito Edric C. | 0% | ||
| Short Daniel S. | 0% | ||
| Spokes, Andrew J. M. | 0% | ||
| Warren, John R. | 0% | ||
| Wehrly, Mark C. | 0% | ||
| BlackRock, Inc. 13G | 5.0% |
7/30/2026
Event 6/30/2026
|
|
|
Commodore Capital LP
13G/A
Amendment 2
|
4.2% |
5/15/2026
Event 3/31/2026
|
|
| Commodore Capital LP | 4.2% | ||
| Commodore Capital Master LP | 4.2% | ||
| Robert Egen Atkinson | 4.2% | ||
| Michael Kramarz | 4.2% | ||
| Janus Henderson Group PLC 13G/A Amendment 2 | 7.2% |
5/15/2026
Event 3/31/2026
|
|
| Todd Harris 13G/A Amendment 1 | 4.8% |
5/14/2026
Event 3/31/2026
|
|
|
Farallon Capital Partners, L.P.
13G/A
Amendment 1
|
6.6% |
5/12/2026
Event 3/31/2026
|
|
| Farallon Capital Partners, L.P. | 1.1% | ||
| Farallon Capital Institutional Partners, L.P. | 1.4% | ||
| Farallon Capital Institutional Partners II, L.P. | 0.2% | ||
| Farallon Capital Institutional Partners III, L.P. | 0.2% | ||
| Four Crossings Institutional Partners V, L.P. | 0.2% | ||
| Farallon Capital Offshore Investors II, L.P. | 2.7% | ||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||
| Farallon Capital F5 Master I, L.P. | 0.3% | ||
| Farallon Healthcare Partners Master, L.P. | 0.4% | ||
| Farallon Partners, L.L.C. | 6.3% | ||
| Farallon Institutional (GP) V, L.L.C. | 0.2% | ||
| Farallon F5 (GP), L.L.C. | 0.3% | ||
| Farallon Healthcare Partners (GP), L.L.C. | 0.4% | ||
| Dapice Joshua J. | 6.6% | ||
| Dreyfuss, Philip D. | 6.6% | ||
| Dunn Hannah E. | 6.6% | ||
| Gehani, Varun N. | 6.6% | ||
| Giauque, Nicolas | 6.6% | ||
| Husen, Avner A. | 6.6% | ||
| Kim, David T. | 6.6% | ||
| Linn, Michael G. | 6.6% | ||
| Luo Patrick (Cheng) | 6.6% | ||
| Roberts, Jr., Thomas G. | 6.6% | ||
| Saito Edric C. | 6.6% | ||
| Short Daniel S. | 6.6% | ||
| Spokes, Andrew J. M. | 6.6% | ||
| Warren, John R. | 6.6% | ||
| Wehrly, Mark C. | 6.6% | ||
|
Canaan XI L.P.
13G/A
Amendment 3
|
1.4% |
4/24/2026
Event 3/31/2026
|
|
| Canaan XI L.P. | 1.4% | ||
| Canaan Partners XI LLC | 1.4% | ||
| Canaan 2020+ Co-Investment L.P. - Series 7 | 0% | ||
| Canaan Partners 2020+ Co-Investment LLC | 0% | ||
|
FMR LLC
13G
|
14.4% |
4/7/2026
Event 3/31/2026
|
|
| FMR LLC | 14.4% | ||
| Abigail P. Johnson | 14.4% | ||
|
RA Capital Management, L.P.
13D/A
Amendment 6
|
21.2% |
3/6/2026
Event 3/4/2026
|
|
| RA Capital Management, L.P. | 21.2% | ||
| Peter Kolchinsky | 21.2% | ||
| Rajeev Shah | 21.2% | ||
| RA Capital Healthcare Fund, L.P. | 17.7% | ||
|
Farallon Capital Partners, L.P.
13G
|
5.6% |
2/20/2026
Event 2/12/2026
|
|
| Farallon Capital Partners, L.P. | 0.9% | ||
| Farallon Capital Institutional Partners, L.P. | 1.2% | ||
| Farallon Capital Institutional Partners II, L.P. | 0.2% | ||
| Farallon Capital Institutional Partners III, L.P. | 0.2% | ||
| Four Crossings Institutional Partners V, L.P. | 0.2% | ||
| Farallon Capital Offshore Investors II, L.P. | 2.4% | ||
| Farallon Capital (AM) Investors, L.P. | 0.1% | ||
| Farallon Capital F5 Master I, L.P. | 0.3% | ||
| Farallon Partners, L.L.C. | 5.3% | ||
| Farallon Institutional (GP) V, L.L.C. | 0.2% | ||
| Farallon F5 (GP), L.L.C. | 0.3% | ||
| Dapice Joshua J. | 5.6% | ||
| Dreyfuss, Philip D. | 5.6% | ||
| Dunn Hannah E. | 5.6% | ||
| Gehani, Varun N. | 5.6% | ||
| Giauque, Nicolas | 5.6% | ||
| Husen, Avner A. | 5.6% | ||
| Kim, David T. | 5.6% | ||
| Linn, Michael G. | 5.6% | ||
| Luo Patrick (Cheng) | 5.6% | ||
| Roberts, Jr., Thomas G. | 5.6% | ||
| Saito Edric C. | 5.6% | ||
| Short Daniel S. | 5.6% | ||
| Spokes, Andrew J. M. | 5.6% | ||
| Warren, John R. | 5.6% | ||
| Wehrly, Mark C. | 5.6% | ||
|
Biotechnology Value Fund L P
13G/A
Amendment 4
|
4.0% |
2/17/2026
Event 12/31/2025
|
|
| Biotechnology Value Fund L P | 2.1% | ||
| BVF I GP LLC | 2.1% | ||
| Biotechnology Value Fund II LP | 1.6% | ||
| BVF II GP LLC | 1.6% | ||
| Biotechnology Value Trading Fund OS LP | 0.2% | ||
| BVF Partners OS Ltd. | 0.2% | ||
| BVF GP Holdings LLC | 3.7% | ||
| BVF Partners L P/IL | 4.0% | ||
| BVF Inc/IL | 4.0% | ||
| Lampert Mark N | 4.0% | ||
| Todd Harris 13G | 5.1% |
2/13/2026
Event 12/31/2025
|
|
|
Canaan XI L.P.
13G/A
Amendment 2
|
5.5% |
2/13/2026
Event 12/31/2025
|
|
| Canaan XI L.P. | 5.5% | ||
| Canaan Partners XI LLC | 5.5% | ||
| Canaan 2020+ Co-Investment L.P. - Series 7 | 0.8% | ||
| Canaan Partners 2020+ Co-Investment LLC | 0.8% | ||
|
Commodore Capital LP
13G/A
Amendment 1
|
6.3% |
11/14/2025
Event 9/30/2025
|
|
| Commodore Capital LP | 6.3% | ||
| Commodore Capital Master LP | 6.3% | ||
| Robert Egen Atkinson | 6.3% | ||
| Michael Kramarz | 6.3% | ||
|
Vestal Point Capital, LP
13G/A
Amendment 1
|
4.5% |
11/14/2025
Event 9/30/2025
|
|
| Vestal Point Capital, LP | 4.5% | ||
| Ryan Wilder | 4.5% | ||
| Janus Henderson Group PLC 13G/A Amendment 1 | 5.4% |
8/14/2025
Event 6/30/2025
|
|
|
RA Capital Management, L.P.
13D/A
Amendment 5
|
22.4% |
6/6/2025
Event 6/4/2025
|
|
| RA Capital Management, L.P. | 22.4% | ||
| Peter Kolchinsky | 22.4% | ||
| Rajeev Shah | 22.4% | ||
| RA Capital Healthcare Fund, L.P. | 18.6% | ||
|
Vestal Point Capital, LP
13G
|
5.4% |
5/15/2025
Event 3/31/2025
|
|
| Vestal Point Capital, LP | 5.4% | ||
| Ryan Wilder | 5.4% | ||
|
Commodore Capital LP
13G
|
5.2% |
5/14/2025
Event 5/7/2025
|
|
| Commodore Capital LP | 5.2% | ||
| Commodore Capital Master LP | 5.2% | ||
| Janus Henderson Group PLC 13G | 5.1% |
5/14/2025
Event 3/31/2025
|
|
|
FMR LLC
13G/A
Amendment 5
|
3.2% |
5/12/2025
Event 3/31/2025
|
|
| FMR LLC | 3.2% | ||
| Abigail P. Johnson | 3.2% | ||
|
RA Capital Management, L.P.
13D/A
Amendment 4
|
20.1% |
3/31/2025
Event 3/27/2025
|
|
| RA Capital Management, L.P. | 20.1% | ||
| Peter Kolchinsky | 20.1% | ||
| Rajeev Shah | 20.1% | ||
| RA Capital Healthcare Fund, L.P. | 16.4% | ||
|
TCG Crossover GP I, LLC
13G
|
5.7% |
3/6/2025
Event 2/27/2025
|
|
| TCG Crossover GP I, LLC | 5.7% | ||
| TCG Crossover Fund I, L.P. | 5.7% | ||
| Chen Yu | 5.7% | ||
|
Biotechnology Value Fund L P
13G/A
Amendment 3
|
7.8% |
2/14/2025
Event 12/31/2024
|
|
| Biotechnology Value Fund L P | 4.0% | ||
| BVF I GP LLC | 4.0% | ||
| Biotechnology Value Fund II LP | 3.2% | ||
| BVF II GP LLC | 3.2% | ||
| Biotechnology Value Trading Fund OS LP | 0.4% | ||
| BVF Partners OS Ltd. | 0.4% | ||
| BVF GP Holdings LLC | 7.3% | ||
| BVF Partners L P/IL | 7.8% | ||
| BVF Inc/IL | 7.8% | ||
| Lampert Mark N | 7.8% | ||
|
Canaan XI L.P.
13G/A
Amendment 1
|
7.4% |
1/21/2025
Event 12/31/2024
|
|
| Canaan XI L.P. | 7.4% | ||
| Canaan Partners XI LLC | 7.4% | ||
| Canaan 2020+ Co-Investment L.P. - Series 7 | 0.9% | ||
| Canaan Partners 2020+ Co-Investment LLC | 0.9% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 3 | 1.35 k | $29.4 k |
| 2026 Q2 | 176 | 70.2 M | $2.24 B |
| 2026 Q1 | 177 | 66.2 M | $2.53 B |
| 2025 Q4 | 136 | 56.8 M | $1.49 B |
| 2025 Q3 | 119 | 55.7 M | $779 M |
| 2025 Q2 | 124 | 56.6 M | $542 M |
| 2025 Q1 | 123 | 53.6 M | $500 M |
| 2024 Q4 | 118 | 48.6 M | $676 M |
| 2024 Q3 | 102 | 47.4 M | $1.11 B |
| 2024 Q2 | 82 | 47.2 M | $755 M |
| 2024 Q1 | 83 | 47.3 M | $776 M |
| 2023 Q4 | 67 | 36.2 M | $501 M |
| 2023 Q3 | 60 | 36.5 M | $502 M |
| 2023 Q2 | 60 | 36.2 M | $617 M |
| 2023 Q1 | 53 | 35.7 M | $573 M |
| 2022 Q4 | 50 | 35.5 M | $269 M |
| 2022 Q3 | 51 | 36.4 M | $320 M |
| 2022 Q2 | 49 | 35.7 M | $256 M |
| 2022 Q1 | 47 | 36.1 M | $387 M |
| 2021 Q4 | 47 | 35.8 M | $504 M |
| 2021 Q3 | 27 | 26.1 M | $457 M |